These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38789398)

  • 21. Inhibitory effects of (-)-epigallocatechin gallate on the life cycle of human immunodeficiency virus type 1 (HIV-1).
    Yamaguchi K; Honda M; Ikigai H; Hara Y; Shimamura T
    Antiviral Res; 2002 Jan; 53(1):19-34. PubMed ID: 11684313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epigallocatechin gallate is a potent inhibitor of cystathionine beta-synthase: Structure-activity relationship and mechanism of action.
    Zuhra K; Petrosino M; Gupta B; Panagaki T; Cecconi M; Myrianthopoulos V; Schneiter R; Mikros E; Majtan T; Szabo C
    Nitric Oxide; 2022 Nov; 128():12-24. PubMed ID: 35973674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiglycation activity of lipophilized epigallocatechin gallate (EGCG) derivatives.
    Wang M; Zhang X; Zhong YJ; Perera N; Shahidi F
    Food Chem; 2016 Jan; 190():1022-1026. PubMed ID: 26213070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigallocatechin-3-gallate promotes wound healing response in diabetic mice by activating keratinocytes and promoting re-epithelialization.
    Ning Y; Yuan Z; Wang Q; He J; Zhu W; Ren DN; Wo D
    Phytother Res; 2024 Feb; 38(2):1013-1027. PubMed ID: 38140774
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
    Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
    J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced Chemotherapeutic Efficacy of PLGA-Encapsulated Epigallocatechin Gallate (EGCG) Against Human Lung Cancer.
    Zhang L; Chen W; Tu G; Chen X; Lu Y; Wu L; Zheng D
    Int J Nanomedicine; 2020; 15():4417-4429. PubMed ID: 32606686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel D-ring analog of epigallocatechin-3-gallate inhibits tumor growth and VEGF expression in breast carcinoma cells.
    Waleh NS; Chao WR; Bensari A; Zaveri NT
    Anticancer Res; 2005; 25(1A):397-402. PubMed ID: 15816564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. (-)-Epigallocatechin gallate (EGCG)-nanoethosomes as a transdermal delivery system for docetaxel to treat implanted human melanoma cell tumors in mice.
    Liao B; Ying H; Yu C; Fan Z; Zhang W; Shi J; Ying H; Ravichandran N; Xu Y; Yin J; Jiang Y; Du Q
    Int J Pharm; 2016 Oct; 512(1):22-31. PubMed ID: 27544847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting Glycolysis with Epigallocatechin-3-Gallate Enhances the Efficacy of Chemotherapeutics in Pancreatic Cancer Cells and Xenografts.
    Wei R; Hackman RM; Wang Y; Mackenzie GG
    Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31590367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The cytotoxic mechanism of epigallocatechin gallate on proliferative HaCaT keratinocytes.
    Chu YW; Liu ST; Yang YL; Huang SM; Wang WM
    J Biomed Sci; 2017 Aug; 24(1):55. PubMed ID: 28810862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tea-break with epigallocatechin gallate derivatives - Powerful polyphenols of great potential for medicine.
    Bakun P; Mlynarczyk DT; Koczorowski T; Cerbin-Koczorowska M; Piwowarczyk L; Kolasiński E; Stawny M; Kuźmińska J; Jelińska A; Goslinski T
    Eur J Med Chem; 2023 Dec; 261():115820. PubMed ID: 37776575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The roles of epigallocatechin-3-gallate in the treatment of neuropathic pain: an update on preclinical in vivo studies and future perspectives.
    Bimonte S; Cascella M; Schiavone V; Mehrabi-Kermani F; Cuomo A
    Drug Des Devel Ther; 2017; 11():2737-2742. PubMed ID: 29066865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigallocatechin gallate inhibits HBV DNA synthesis in a viral replication - inducible cell line.
    He W; Li LX; Liao QJ; Liu CL; Chen XL
    World J Gastroenterol; 2011 Mar; 17(11):1507-14. PubMed ID: 21472112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigallocatechin-3-Gallate (EGCG) Suppresses Pancreatic Cancer Cell Growth, Invasion, and Migration partly through the Inhibition of Akt Pathway and Epithelial-Mesenchymal Transition: Enhanced Efficacy when Combined with Gemcitabine.
    Wei R; Penso NEC; Hackman RM; Wang Y; Mackenzie GG
    Nutrients; 2019 Aug; 11(8):. PubMed ID: 31405071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigallocatechin-3-Gallate, the Main Polyphenol in Green Tea, Inhibits Porcine Epidemic Diarrhea Virus
    Huan C; Xu W; Ni B; Guo T; Pan H; Jiang L; Li L; Yao J; Gao S
    Front Pharmacol; 2021; 12():628526. PubMed ID: 33692691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antifibrotic properties of epigallocatechin-3-gallate in endometriosis.
    Matsuzaki S; Darcha C
    Hum Reprod; 2014 Aug; 29(8):1677-87. PubMed ID: 24876174
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of binding interactions of (-)-epigallocatechin-3-gallate from green tea and lipase.
    Wu X; He W; Yao L; Zhang H; Liu Z; Wang W; Ye Y; Cao J
    J Agric Food Chem; 2013 Sep; 61(37):8829-35. PubMed ID: 23971865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir.
    Oliveira M; Ibanescu RI; Pham HT; Brenner B; Mesplède T; Wainberg MA
    AIDS; 2016 Sep; 30(15):2267-73. PubMed ID: 27367488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical development of the green tea catechin, epigallocatechin gallate, as an HIV-1 therapy.
    Nance CL; Siwak EB; Shearer WT
    J Allergy Clin Immunol; 2009 Feb; 123(2):459-65. PubMed ID: 19203663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of (-)-epigallocatechin-3-gallate as a potential agent for blocking infection by grass carp reovirus.
    Wang H; Liu W; Yu F; Lu L
    Arch Virol; 2016 Apr; 161(4):1053-9. PubMed ID: 26758731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.